期刊文献+
任意字段
题名或关键词
题名
关键词
文摘
作者
第一作者
机构
刊名
分类号
参考文献
作者简介
基金资助
栏目信息

血小板糖蛋白Ⅱb/Ⅲa受体拮抗剂研究现状 被引量：1

Current study of platelet glycoprotein Ⅱb/Ⅲa receptors antagonist
下载PDF
导出
摘要 血小板糖蛋白Ⅱb/Ⅲa受体是各种血小板聚集剂导致血栓形成的最后通道。综述上市和部分开发中的血小板糖蛋白Ⅱb/Ⅲa受体拮抗剂类药物。 The final common pathway to thrombus formation involves platelets aggregation via their glycoprotein Ⅱb/Ⅲa receptors. In this article, glycoprotein（GP） Ⅱb/Ⅲa antagonists launched or developed in recent years were reviewed.
作者 张海军 陈国华
机构地区 中国药科大学药物化学教研室
出处 《海峡药学》 2007年第6期8-11,共4页 Strait Pharmaceutical Journal
关键词 血小板聚集 GpⅡb/Ⅲa受体 GpⅡb/Ⅲa受体拮抗剂 Platelet aggregation Glycoprotein （GP） Ⅱb／Ⅲa receptors GPⅡb／Ⅲa antagonists
分类号 R937.2 [医药卫生—生药学]
  • 相关文献

参考文献30

  • 1Topol EJ.Patelet glycoprotein Ⅱb/Ⅲa receptor antagonists in coronary artery disease[J].Eur Heart J,1996,17:9 ～ 10.
  • 2Breton HL,Plow EF,Topol EJ,et al.Role of plateles in resenosis after percutaneous coronary revascularization[J].J AM Coll Cardiol,1996,28:1643 ～ 1644.
  • 3Szabo S,Etzel D,Ehlers R,et al.Combined thrombolysis with abciximab favourably influences platelet-leukocyte interactions and platelet activation in acute myocardial infarction[J].J Thromb Thrombolysis.2005,20(3):155 ～ 161.
  • 4Kereiakes DJ.Inflammation as a therapeutic target:a unique role for abciximab[J].Am Heart J,2003,146(3 suppl):1.
  • 5De Queiroz,Fernandes Araujo JQ,Veloso HH,et al.Efficacy and safety of abciximab on acute myocardial infarction treated with percutaneous coronary interventions:a meta-analysis of randomized,controlled trials[J].Am Heart J,2004,148 (6):937 ～943.
  • 6Godicke J,Flather M,Noc M,et al.Early versus periprocedural administration of abciximab for primary angioplasty:a pooled analysis of 6 studies[J].Am Heart J,2005,150(5):1015.
  • 7Suzuki K,Sato K,Kamohara M,et al.Comparative studies of a humanized anti-glycoprotein Ⅱb/Ⅲa monoclonal antibody,YM337,and abciximab on in vitro antiplatelet effect and binding properties[J].Biol Pharm Bull,2002,25(8):1006 ～ 1012.
  • 8Graff J,Klinkhardt U,Westrup D,et al.Pharmacodynamic characterization of the interaction between the glycoprotein Ⅱb/Ⅲa inhibitor YM337 and unfractionated heparin and aspirin in humans[J].Br J Clin Pharmacol,2003,56 (3):321 ～ 326.
  • 9Goa KL,Noble S.Eptifibatide,a review of its use in patients with acute coronary syndromes and/orundergoing percutaneous coronary intervention[J].Drugs,1999,57 (3):439 ～ 462.
  • 10Gretler DD,Guerciolini R,Williams PJ.Pharmacokinetic and pharmacodynamic properties of eptifibatide in subjects with normal or impaired renal function[J].Clin Ther,2004,26(3):390 ～398.

同被引文献17

  • 1World Health Organization. Cardiovasular diseases [EB/OL]. http://www.who.int/cardiovascular diseases/en/index.html.2013-3- 27/2013-5-20.
  • 2Stangl PA, Lewis S. Review of currently available GP 11 b/ma inbibitors and their role in peripheral vascular interventions[J]. Semin Intervent Radiol, 2010, 27(4): 412-421.
  • 3Harder S, Kirchmaier CM, Krzywanek HJ, et al. Pharmacokinetics and pharmacodynamic effects of a new antibody glycoprotein 1I b/IlJa inhibitor (YM337)in healthy subjects[J]. Circulation. 1999, 100(11):1175-1181.
  • 4Akkerhuis KM, Neuhaus KL, Wilcox RC, et al. Safetyand preliminary efficacy of one month glycoprotein U b/ma inhibition with lefradafiban in patients with acute coronary syndromes without ST-elevation; a phase II study[J].Eur Heart J, 2000, 21(24): 2042-2055.
  • 5Topol EJ, Ferguson J J, Weisman HI:, et al. Long-term protection from myocardial ischemic events in a randomized trial of brief integrin beta3 blockade with percutaneous coronary intervention [J]. JAMA, 1997,278: 479-484.
  • 6Labinaz M, Ho C, Banerjee S, Martin J, et al. Meta-analysis of clinical efficacy and bleeding risk with intravenous glycoprotein II b/Ilia antagonists for percutaneous coronary intervention[J]. Can J Cardiol. 2007,23(12):963-970.
  • 7Stone GW, Bertrand ME, Moses JW, et al.Routine upstream initiation vs deferred selective use ofglycoprotein IIb/mainhibitors in a cute coronary syndromes: the ACUITY Yiming trial[J]. JAMA,2007,297(6):591.
  • 8Rezkalla SH, Kloner RA. Noreflowphenomenon[J]. Circulation, 2002, 105:656-662.
  • 9Kandzari DE, Hasselblad V, Tcheng JE, et al. Improved clinical outcomes with abciximab therapy inacutemyocardial infarction: asystematicoverviewof randomized clinical trials[J]. AmHeart J, 2004, 147: 457-462.
  • 10Said SM, Hahn J, Schleyer E, et al. Glycoprotein I~ b/Illa inhibitor- induced thrombocytopenia: diagnosis and treatment[J]. Clin Res Cardiol. 2007, 96(2):61-69.

引证文献1

二级引证文献1

海峡药学
2007年 第6期

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部